Results 191 to 200 of about 5,069,870 (397)

The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2001
Jeff L. Staudinger   +12 more
semanticscholar   +1 more source

Natural Products as Geroprotective Modulators in Diabetic Nephropathy: A Mechanistic Framework Integrating Aging Hallmarks and the AMPK–SIRT1–Nrf2 Axis

open access: yesAging and Cancer, EarlyView.
Natural products target the aging kidney in diabetic nephropathy by restoring the AMPK–SIRT1–Nrf2 axis, reducing oxidative stress, inflammation, fibrosis, and cellular senescence while enhancing mitochondrial biogenesis and antioxidant defenses.
Sherif Hamidu   +8 more
wiley   +1 more source

Nuclear Receptors [PDF]

open access: yesCell, 2003
Belandia, Borja, Parker, Malcolm G.
openaire   +1 more source

Endogenous bile acids are ligands for the nuclear receptor FXR/BAR.

open access: yesMolecules and Cells, 1999
Haibo Wang   +4 more
semanticscholar   +1 more source

NR4A1 Exerts Pro‐Tumor Role in Glioblastoma via Inducing xCT/GPX4‐Regulated Ferroptosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Purpose This study investigates NR4A1's paradoxical roles in glioblastoma (GBM) progression, focusing on its mechanistic link to ferroptosis regulation. We aimed to resolve conflicting reports of NR4A1 as both an oncogene and a tumor suppressor by defining its transcriptional control over xCT/GPX4‐mediated iron homeostasis and its clinical ...
Peng Tao   +10 more
wiley   +1 more source

CRM1 Is an Export Receptor for Leucine-Rich Nuclear Export Signals

open access: yesCell, 1997
M. Fornerod   +3 more
semanticscholar   +1 more source

Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy